BCTX Stock Summary and Trading Ideas (Briacell Therapeutics Corp. - Common Shares | NASDAQ:BCTX)

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Briacell Therapeutics Corp. - Common Shares trades on the NASDAQ stock market under the symbol BCTX.

As of May 22, 2026, BCTX stock price declined to $3.49 with 317,092 million shares trading.

BCTX has a beta of 2.33, meaning it tends to be more sensitive to market movements. BCTX has a correlation of 0.04 to the broad based SPY ETF.

BCTX has a market cap of $25.30 million. This is considered a Sub-Micro Cap stock.

Last quarter Briacell Therapeutics Corp. - Common Shares reported $0 in Revenue and -$2.58 earnings per share. This fell short of revenue expectation by $-840,000 and exceeded earnings estimates by $2.26.

In the last 3 years, BCTX traded as high as $1,138.49 and as low as $2.98.

BCTX has underperformed the market in the last year with a price return of -89.8% while the SPY ETF gained +29.1%. BCTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.0% and -16.7%, respectively, while the SPY returned +8.4% and +1.1%, respectively.

BCTX support price is $3.53 and resistance is $3.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCTX shares will trade within this expected range on the day.